Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection-Reference-Cited by-同舟云学术

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection

Published:2017-01 Issue:1 Volume:152 Page:164-175.e4
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Kwo Paul,Gane Edward J.,Peng Cheng-Yuan,Pearlman Brian,Vierling John M.,Serfaty Lawrence,Buti Maria,Shafran Stephen,Stryszak Paul,Lin Li,Gress Jacqueline,Black Stuart,Dutko Frank J.,Robertson Michael,Wahl Janice,Lupinacci Lisa,Barr Eliav,Haber Barbara

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference26 articles.

1. Harvoni [package insert]. Foster City, CA; Gilead Sciences, Inc.; 2016.

2. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection;Afdhal;N Engl J Med,2014

3. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial;Pianko;Ann Intern Med,2015

4. EPCLUSA [package insert]. Foster City, CA; Gilead Sciences, Inc; 2016.

5. Zepatier [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2016.

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety considerations in the management of hepatitis C and HIV co-infection;Expert Opinion on Drug Safety;2023-04-27

2. Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance;Annals of Hepatology;2023-03

3. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C;World Journal of Gastroenterology;2023-02-14

4. Elbasvir/grazoprevir in children aged 3–18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study;Hepatology Communications;2023-02-14

5. Efficacy and Safety of Adding Ribavirin to Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C Infection- a Systematic Review and Meta-Analysis;2023